Across TCGA pan-cancer cohorts, CRLF3P2 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of CRLF3P2’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where CRLF3P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CRLF3P2 is over-expressed in tumor.
COAD and KIRC are the cancer types where CRLF3P2 tumor–normal differential expression is most reproducible.